HA
MRNA icon

Herold Advisors’s Moderna MRNA Stock Holding History

Herold Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,405
Closed -$286K – 278
2024
Q2 		$286K Hold
2,405
– – 0.07% 220
2024
Q1 		$256K Buy
+2,405
New +$242K 0.06% 235
2023
Q3 		– Sell
-1,925
Closed -$234K – 256
2023
Q2 		$234K Buy
1,925
+100
+5% +$13.3K 0.07% 218
2023
Q1 		$280K Buy
1,825
+235
+15% +$38.8K 0.1% 192
2022
Q4 		$286K Buy
+1,590
New +$260K 0.12% 162
2022
Q2 		– Sell
-290
Closed -$50K – 483
2022
Q1 		$50K Buy
+290
New +$48.8K 0.02% 381
2021
Q4 		– Sell
-150
Closed -$57K – 470
2021
Q3 		$57K Buy
+150
New +$55.3K 0.02% 355

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Herold Advisors's MRNA Position: Q3 2024 in Review

Herold Advisors sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,405 shares — an estimated $286K sold.

Herold Advisors first reported a position in MRNA in Q3 2021 and held it in 7 quarters. The position peaked at $286K in Q4 2022. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Herold Advisors reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Herold Advisors sold 2,405 Moderna shares in Q3 2024, an estimated $286K.
  • Herold Advisors first reported a position in Moderna in Q3 2021 and held it in 7 quarters.
  • Herold Advisors's Moderna position peaked at $286K in Q4 2022.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Herold Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.